Cargando…

Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study

BACKGROUND: In patients with non-small cell lung cancer (NSCLC), both chronic obstructive pulmonary disease (COPD) and systemic inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have significant association with prognosis. NLR and PLR also predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jeong Uk, Kang, Hye Seon, Yeo, Chang Dong, Kim, Ju Sang, Park, Chan Kwon, Kim, Yong Hyun, Kim, Jin Woo, Kim, Seung Joon, Lee, Sang Haak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753914/
https://www.ncbi.nlm.nih.gov/pubmed/33363365
http://dx.doi.org/10.2147/COPD.S274354
_version_ 1783626085967069184
author Lim, Jeong Uk
Kang, Hye Seon
Yeo, Chang Dong
Kim, Ju Sang
Park, Chan Kwon
Kim, Yong Hyun
Kim, Jin Woo
Kim, Seung Joon
Lee, Sang Haak
author_facet Lim, Jeong Uk
Kang, Hye Seon
Yeo, Chang Dong
Kim, Ju Sang
Park, Chan Kwon
Kim, Yong Hyun
Kim, Jin Woo
Kim, Seung Joon
Lee, Sang Haak
author_sort Lim, Jeong Uk
collection PubMed
description BACKGROUND: In patients with non-small cell lung cancer (NSCLC), both chronic obstructive pulmonary disease (COPD) and systemic inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have significant association with prognosis. NLR and PLR also predict mortality in patients with COPD alone. A combination of the two parameters may be helpful in a more individualized approach for predicting prognosis in NSCLC. METHODS: Medical records of patients with stage IIIB and IV NSCLC from January 2012 to January 2018 in seven university hospitals were reviewed. Patients were categorized into four subgroups based on pulmonary function test results and cutoffs for NLR or PLR. RESULTS: A total of 277 patients were evaluated and categorized into non-COPD and COPD groups; 194 patients were in the non-COPD group and 83 patients were in the COPD group. The non-COPD group showed significantly longer overall survival (OS) compared with the COPD group (P = 0.019). Median survival was significantly different between high/low PLR groups (P < 0.001), between high/low NLR groups (P = 0.001), and between high/low c-reactive protein (CRP) groups (P < 0.001). PLR, NLR and CRP showed significant correlations with each other. PLR showed a significant negative linear correlation with FVC (absolute) (r = −0.149, P = 0.015), FVC (%) (r = −0.192, P = 0.002), DLCO (absolute) (r = −0.271, P < 0.001), DLCO (%) (r = −0.139, P = 0.032), and NLR (r = 0.718, P < 0.001). In the multivariate analysis, the high PLR, COPD sub-group showed significantly higher risk for mortality (HR 2.066 (1.175–3.633), P = 0.012) compared with the low-PLR non-COPD group. However, COPD-NLR subtype was not an independent predictor for OS. CONCLUSION: A combination of COPD status and PLR may be a cost-effective and readily available prognostic marker in patients with advanced NSCLC.
format Online
Article
Text
id pubmed-7753914
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77539142020-12-23 Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study Lim, Jeong Uk Kang, Hye Seon Yeo, Chang Dong Kim, Ju Sang Park, Chan Kwon Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Lee, Sang Haak Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: In patients with non-small cell lung cancer (NSCLC), both chronic obstructive pulmonary disease (COPD) and systemic inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have significant association with prognosis. NLR and PLR also predict mortality in patients with COPD alone. A combination of the two parameters may be helpful in a more individualized approach for predicting prognosis in NSCLC. METHODS: Medical records of patients with stage IIIB and IV NSCLC from January 2012 to January 2018 in seven university hospitals were reviewed. Patients were categorized into four subgroups based on pulmonary function test results and cutoffs for NLR or PLR. RESULTS: A total of 277 patients were evaluated and categorized into non-COPD and COPD groups; 194 patients were in the non-COPD group and 83 patients were in the COPD group. The non-COPD group showed significantly longer overall survival (OS) compared with the COPD group (P = 0.019). Median survival was significantly different between high/low PLR groups (P < 0.001), between high/low NLR groups (P = 0.001), and between high/low c-reactive protein (CRP) groups (P < 0.001). PLR, NLR and CRP showed significant correlations with each other. PLR showed a significant negative linear correlation with FVC (absolute) (r = −0.149, P = 0.015), FVC (%) (r = −0.192, P = 0.002), DLCO (absolute) (r = −0.271, P < 0.001), DLCO (%) (r = −0.139, P = 0.032), and NLR (r = 0.718, P < 0.001). In the multivariate analysis, the high PLR, COPD sub-group showed significantly higher risk for mortality (HR 2.066 (1.175–3.633), P = 0.012) compared with the low-PLR non-COPD group. However, COPD-NLR subtype was not an independent predictor for OS. CONCLUSION: A combination of COPD status and PLR may be a cost-effective and readily available prognostic marker in patients with advanced NSCLC. Dove 2020-12-14 /pmc/articles/PMC7753914/ /pubmed/33363365 http://dx.doi.org/10.2147/COPD.S274354 Text en © 2020 Lim et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lim, Jeong Uk
Kang, Hye Seon
Yeo, Chang Dong
Kim, Ju Sang
Park, Chan Kwon
Kim, Yong Hyun
Kim, Jin Woo
Kim, Seung Joon
Lee, Sang Haak
Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study
title Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study
title_full Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study
title_fullStr Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study
title_full_unstemmed Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study
title_short Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study
title_sort impact of combined chronic obstructive pulmonary disease status and systemic inflammation on outcome of advanced nsclc: multicenter retrospective cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753914/
https://www.ncbi.nlm.nih.gov/pubmed/33363365
http://dx.doi.org/10.2147/COPD.S274354
work_keys_str_mv AT limjeonguk impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy
AT kanghyeseon impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy
AT yeochangdong impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy
AT kimjusang impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy
AT parkchankwon impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy
AT kimyonghyun impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy
AT kimjinwoo impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy
AT kimseungjoon impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy
AT leesanghaak impactofcombinedchronicobstructivepulmonarydiseasestatusandsystemicinflammationonoutcomeofadvancednsclcmulticenterretrospectivecohortstudy